CONTACT INFORMATION for Teva
SAMPLE LETTER FOLLOWS

TEVA PHARMACEUTICALS, CHIEF OFFICERS
Dan S. Suesskind, Chief Financial Officer: 972 2 589 2840; dan@teva.co.il,
Dan.Suesskind@teva.co.il

President and CEO, Teva North America: 215-591-3030; George.Barrett@teva.co.il

Director, Investor Relations, Teva North America: 215-591-8912; kevin.mannix@tevausa.com

Israel Makov, President & CEO: 972 3 926 7202; israel.makov@teva.co.il

Group Vice President International: 972 9 863 9741; chaim.hurvitz@teva.co.il

Vice-President, HR: 00 972 3 926 7231; haim.benjamini@teva.co.il

Vice-President, Business Development: 972 3 926 7463; eli.shohet@teva.co.il

Group Vice-President, Global Products: 972 3 926 7239; ben-zion.weiner@teva.co.il

Vice-President, Safety and Ecology: 972 3 926 7650; mike.netz@teva.co.il

Vice-President Israel Pharmaceutical Sales: 9 863 1436; mike.netz@teva.co.il

Vice-President and Chief Technology Officer: 972 3 926 7572; rodney.kasan@teva.co.il

Vice President, Global Products Division: 926 7578; moshe.manor@teva.co.il

Vice-President, Innovative R & D: 972 9 863 9996; david.reisman@teva.co.il

Vice-President, Israel Pharmaceutical Operations: 00 972 9 764 8224; david.reisman@teva.co.il

Vice-President Strategic business planning: 972 3 926 7277; aharon.schwartz@teva.co.il

Vice-President Global Operations: 972 2 589 2831; jacob.winter@teva.co.il

Vice-President, API Division: arik.yaari@teva.co.il

Internal Auditor: 972 3 926 7380; ron.grupel@teva.co.il

General Counsel and Company Secretary: 972 3 926 72 97; uzi.karniel@teva.co.il

Group Vice-President, Europe, President & CEO: meron.mann@tevaeu.com

President and CEO Teva Pharmaceuticals USA: 215-591-3030; george.barrett@tevausa.com

William A. Fletcher, Group Vice-President, USA CEO: 215-591-8800; fletcher@tevausa.com

Christopher Pelloni, Vice-President, Global Generic R&D: 215-591-3184; chris.pelloni@tevausa.com

Director: 972 3 92 67 704, mobile: 972 50 332 463; eli.hurvitz@teva.co.il
ALL EMAILS (THOSE ABOVE, PLUS ADDITIONAL, IN BLOCKS OF 25):

SENDING EMAILS IN BULK:

1. Some emails in large blocks will inevitably bounce.
   WHY? They are obtained from websites that haven't been updated.
   They are disabled or blocked in response to ongoing activist campaigns.

2. To BLIND-COPY a block of emails, so recipients don’t see huge email list:
   * COPY/PASTE a block of emails into the Bcc: line of your email.
   * TYPE YOUR OWN EMAIL in the To: line.
   * Personalize, sign, COPY/PASTE letter portion of alert into body of your email.
   * Click SEND.
   * REPEAT FOR EACH BLOCK OF EMAILS.
   * Email programs differ in terms of how many addresses you can send to at one time.
   Yahoo, Outlook, Hotmail: Separate emails by a comma (,) and do not exceed 50.

   dan@teva.co.il, Dan.Suesskind@teva.co.il, George.Barrett@teva.co.il, kevin.mannix@tevausa.com,
   israel.makov@teva.co.il, chaim.hurvitz@teva.co.il, haim.benjamin@teva.co.il, eli.shohet@teva.co.il,
   ben-zion.weiner@teva.co.il, yehuda.arad@teva.co.il, mike.netz@teva.co.il, rodney.kasan@teva.co.il,
   moshe.manor@teva.co.il, irit.pinchasi@teva.co.il, david.reisman@teva.co.il, aharon.schwartz@teva.co.il,
   jacob.winter@teva.co.il, arik.yaari@teva.co.il, ron.grupel@teva.co.il, uzikarniel@teva.co.il,
   meron.mann@tevaeu.com, george.barrett@tevausa.com, fletcher@tevausa.com,
   chris.pelloni@tevausa.com, eli.hurvitz@teva.co.il

dolores.stolzer@tevausa.com, kathy.barger@tevausa.com, maria.giersch@tevausa.com,
wilma.schouwenburg@tevaeu.com, rob.o'neill@tevausa.com, nili.zaliet@teva.co.il,
gideon.ben-amar@teva.co.il, eli.elgali@teva.co.il, benny.perlman@teva.co.il, eitan.kin@teva.co.il,
arie.spiegelman@teva.co.il, yosef.raguan@teva.co.il, tal.zchrea@teva.co.il, tal.zchrea@teva.co.il,
zohar.yalloz@teva.co.il, nir.levav@teva.co.il, dov.meshel@teva.co.il, coxubic@teva.co.il,
john.hassler@tevaneuro.com, john.shaw@tevaneuro.com, tammy.maclean@tevaneuro.com,
marian.feltens@tevaneuro.com, Mike.Pursel@tevaneuro.com

melissa.nash@tevaneuro.com, tevaneuro@tevaneuro.com, bryce.miller@tevaneuro.com,
sheila.zinn@tevaneuro.com, jason.baldwin@tevaneuro.com, rivka.kreitman@tevaneuro.com,
lori.messner@tevaneuro.com, jeff.washburn@tevaneuro.com, sharedsolutions@tevaneuro.com,
uri.dreckshage@tevaneuro.com, ginette.dumoulin@tevaneuro.com, tdietrich@tevaneuro.com,
don.stout@tevusa.com, dennis.ferrell@tevusa.com, dstolzer@tevusa.com, cpelloni@tevusa.com,
dferrell@TevaUSA.com, paul.witmer@tevusa.com, jack.loughery@tevusa.com,
michele.wilhelm@tevusa.com, mguyen@tevusa.com, Michael.Furman@tevusa.com,
Kelly.Tolton@tevusa.com, daniel.loss@tevusa.com, kevin.sturtevant@tevusa.com

Gbarrett@tevusa.com, diane.morales@tevusa.com, rbenson@tevusa.com, oncotest@teva.co.il,
smadar.nisimov@teva.co.il, rel@teva.co.il, Rachel.Nagar@teva.co.il, erwin-s@teva.co.il,
Reuven.Leshem@teva.co.il, ronen.klapper@teva.co.il, Diana.Yankovitch@teva.co.il,
Amit.Katz@teva.co.il, rachel.efram@teva.co.il, Zeev.Elkoski@teva.co.il, ammon.michael@teva.co.il,
shahaf.edut@teva.co.il, Yossi.Shapira@Teva.co.il, gil.barzilay@teva.co.il,
dalia.medini-green@teva.co.il, david.silver@teva.co.il, Santiago.Lni@teva.co.il, dror.philos@tevapa.co.il,
Gary.Littwin@teva.co.il, joel.lubell@teva.co.il

Nili.Sukenik@teva.co.il, boris.pevzner@tevapa.co.il, liraz.kalif@teva.co.il, john.hassler@tevaneuro.com,
larry.downey@tevaneuro.com, kd.schulz.muehlenbein@teva.de, daniela.dietz@teva.de,
jorg.max.ulrich@teva.de, gabriella.biro@teva.hu, peter.fabian@teva.hu, viktoria.kulcsar@teva.hu,
gabor.suranyi@teva.hu, maria.dioszegi@teva.hu, maria.lukacs@teva.hu, istvan.hegedus@teva.hu,
sandor.sipos@teva.hu, anita.suto@teva.hu, nora.kalmanczhey@teva.hu, kariera@teva.cz,
udi.ashash@teva.co.il, jaap.bruynzeel@teva.co.il, ido.weinstein@tevauracao.com,
ibolya.bertok@teva.hu, egeszsegunkre@teva.hu

nili.zaliet@teva.co.il, David.Gibiser@tevausa.com, Ray.Duggan@tevausa.com, Phillip.Young@tevaneuro.com, ofer.lev@teva.co.il, alex.staroselsky@teva.co.il, rami.moskovitz@teva.co.il, victor.shriker@teva.co.il, moche.ifrah@teva.co.il, avner.finger@teva.co.il, kariera@teva.sk, liliach.galansky@teva.co.il, contact@tevafrance.com, privacy@tevaneuro.com, hr-gollo@teva.hu, h.r@tevaneuro.com, TevaUS_Network@tevausa.com, jobsoper.division@teva.co.il, pr@teva.co.il, postmasters@teva.cz, teva.polska@teva.pl, info@tevausa.com, tevagenerics@teva.de, info@tevabelgium.be, infogate@tevausa.com, infogate@tevausa.com, infocanada@tevaneuro.com

TEVA STREET ADDRESSES

TEVA PHARMACEUTICALS, CORPORATE HEADQUARTERS
5 Basel St. Petach Tikva 49131, Israel
ph: +972-3-9267267; fax: +972-3-9234050

NETHERLANDS
Teva Pharmaceuticals Europe B.V., European Headquarters
Industrieweg 23, P.O.B. 206, 3640 AE Mijdrecht, The Netherlands
ph: +31-29-7290200; fax: +31-29-7290299

Pharmachemie B.V. / Pharmaceutical Development (manufacture and marketing)
Swensweg 5, P.O.B. 552, 2003 RN Haarlem, The Netherlands
ph: +31-23-5147147, +31-23-5312879

Plantex Chemicals B.V. / API Marketing
Industrieweg 23, P.O.B. 206, 3640 AE Mijdrecht, The Netherlands
ph: +31-29-7290200, +31-29-7290299

UNITED KINGDOM
Teva Pharma UK / Innovative Pharmaceuticals
The Gate House, Gatehouse Way, Aylesbury
Bucks HP19 8DB, Great Britain
ph: +44-129-6719768; fax: +44-129-6719769

Teva UK Limited / Pharmaceutical Products
Leeds Business Park, 18 Bruncliffe Way, Morley
Leeds LS27 OJG, Great Britain
ph: +44-113-238-0099; fax: +44-113-201-3936

TEVA UK Limited (Packaging Centre)
Brampton Road, Hampden Park, Eastbourne
East Sussex BN22 9AG
ph: +44 (0) 1323 501111; fax: +44 (0) 1323 512812

HUNGARY
Teva Pharmaceutical Works Ltd. Hungary
Pharmaceutical & API Development (manufacture and marketing)
13 Pallagi St., H-4042 Debrecen, Hungary
ph: +36-52-515100; fax: +36-52-311633
Teva Hungary Ltd. / Pharmaceutical Products
Rackoczi ut 70-72 H-1074, Budapest, Hungary
ph: +36-1-2886400; fax: +36-1-2886410

FRANCE
Teva Classics France / Pharmaceutical and Innovative Products
Immeuble le Palatin 1, 1 cours du Triangle de l'Arche
92936 Puteaux (Paris), La Defense Cedex 12, France
ph: +33-1-55-91-7800; fax: +33-1-55-91-7941

GERMANY
Teva Group Germany / Pharmaceutical Products
Kandelstrasse 10 D-79199 Kirchzarten, Germany
ph: +49-6105-976760, +49-7661-984501
fax: +49-6105-976761, +49-7661-984569

ITALY
Teva Pharma Italia S.r.l. / Pharmaceutical Products
Via Giulio Richard 7 (floor 8), 20143 Milano, Italy
ph: + 39-02-8917981; fax: +39-02-89179825

Teva Pharmaceutical Fine Chemicals S.r.l. / API Production
Strada Statale Briantea 83, 23892 Bulciago (LC), Italy
ph: +39-031-8721; fax: +39-031-872-353

Prosintex Industrie Chimiche Italiane S.r.l. / API Manufacturing
Via Enrico Fermi 20/26, 20019 Settimo Milanese (MI), Italy
ph: +39-02-335571; fax: +39-02-33501123

BELGIUM
Teva Belgium / Pharmaceutical Products
Laarstraat 16, 2610 Wilrijk-Antwerpen, Belgium
ph: +32-3-8207373; fax: +32-3-8207371

CZECH REPUBLIC
Teva Pharmaceuticals CR, s.r.o. / Pharmaceutical Products
Drazni 7, 627 00 Brno, Czech Republic
ph: +420-5-48226521; fax: +420-5-48226525

SWITZERLAND
Teva Suisse, Marketing Office
Industriestrasse 111, CH-4147 Aesch / BL, Switzerland
ph: +41 61 756 97 50; fax: + 41 61 756 97 55

Sicor Europe S.A. / Marketing Offices and API R&D
Via San Salvatore 7, CH-6900 Lugano, Switzerland
ph: +41-91-994-9461; fax: +41-91-994-97

SWEDEN
Teva Sweden AB / Pharmaceutical Products
Sundstorget 2, Helsingborg
P.O. Box 1070, 251 10 Helsingborg, Sweden
ph: +46-42-121100; fax: +46-42-121108
SPAIN
Teva API International Spain / API Marketing
Rambla Catalunya, 66, 08008 Barcelona, Spain
ph: +34-93-4677161; fax: +34-93-2160314

Teva Generics Spain / Pharmaceutical Products
C/Guzman el Bueno 133 4th floor, 28003 Madrid, Spain
ph: +34-91-535-91-80; fax: +34-91-535-91-83

PORTUGAL
Teva Pharma Portugal Ltd. / Pharmaceutical Products
Lagoas Park , Ed 1, Piso 3, 2740-264 Porto Salvo, Portugal

RUSSIA
Teva Moscow, Representative Office
Nauchny proezd 8 office 226, Moscow 117246, Russia
ph: +7-095-7211739; fax: +7-095-9562803

NORTH AMERICA
Teva Pharmaceuticals USA / Pharmaceutical Development (manufacture and marketing)
1090 Horsham Rd. P.O.B. 1090, North Wales, PA 19454, USA

Plantex USA / API Marketing
2 University Plaza, Suite 305, Hackensack, NJ 07601, USA
ph: +1-201-343-4141; fax: +1-201-343-3833

Teva Sicor / Pharmaceutical Development (manufacture and marketing)
19 Hughes, Irvine, CA 92618, USA
ph: +1-800-729-9991; fax: +1-949-855-8210

Teva Neuroscience / Innovative Pharmaceuticals
901 E. 104th Street, Suite 900, Kansas City, MO 64131, USA
ph: +1-816-508-5000; fax: +1-816-508-5016

Teva Biocraft / API Production
5000 Snyder Drive, Mexico, MO 65265, USA

Novopharm / Pharmaceutical Development (manufacture and marketing)
30 Novopharm Court, Toronto, Ontario, M1B 2K9 Canada

Teva Neuroscience Canada / Innovative Pharmaceuticals
999, de Maisonneuve Blvd. West, Suite 550
Montreal, Quebec, H3A 3L4 Canada
ph: +1-866-329-0095, +514-878-0798

SAMPLE LETTER NEXT PAGE
Dear Sir/Madam:

Please accept my comments, sent with concern for the welfare of animals used in the development of Teva Pharmaceutical products. I understand Teva contracts a research laboratory cited for falsification of data and cruelty to animals.

While I am confident no one at your firm condones animal abuse, I am surprised to learn Teva regularly employs Huntingdon Life Sciences (HLS) to conduct its animal experiments. From 1989 to 2006, HLS has acquired: Multiple breaches of the U.S. Animal Welfare Act, the arrest of workers on animal cruelty charges, more than 520 infringements of Good Laboratory Practice in England, and a $50,000 payoff to the U.S. Agriculture Department for misstated records and animal welfare violations. HLS has a criminal record in the UK for failure to file company accounts on time.

Over the course of six investigations, HLS has been exposed for incompetence, fabricated records, and profound animal cruelty. As recently as late 2005, two former employees from the HLS Beagle Unit left their jobs distressed over the animal suffering they witnessed daily for 12 months.

According to tape-recorded testimonial from the two employees, animals are improperly overdosed with test drugs. Dogs are inadequately anesthetized before invasive procedures, such as painful extraction of bone marrow from the chest bone, among others.

One employee recounts daily blood-draw contests to see who could cram in the most before a break. Careless workers transferred blood into the wrong tubes. "One license holder I worked with would go in and out about five times with the same needle, not hitting the vein. Some dogs would struggle. I saw co-workers grab them by the scruff, shout and swear at them, swing them by the scruff and slap them."

I was shocked to view substantiated accounts of HLS technicians who nonchalantly kill dogs by flooding their lungs with toxic materials meant for the animals’ stomach. In one investigative video clip, a technician repeatedly punches a screaming 4-month-old beagle pup in the face. During a supposedly post-mortem dissection, another tech slices into the chest of a convulsing monkey.

Undoubtedly, you find this callous treatment of animals as unacceptable as I do. I hope you will join the long list of customers, suppliers and financiers who no longer risk credibility by association with Huntingdon Life Sciences.

I also urge Teva to reevaluate its testing protocol and condense animal experiments whenever possible. Cost-effective and expedient non-animal systems are rapidly replacing old-fashioned animal studies. Options range from cell and tissue cultures and “structure-activity relationship” models to genetic/protein analysis and numerous other non-animal research tools.

Please make the ethically responsible decision to sever ties with HLS and modernize your product testing with methods that are not only more relevant to human health, but also humane.

Thank you,